PURE BIOSCIENCE, INC.
AI Executive Summary
AI-powered analysis of 10-Q filing content
Pure Bioscience exhibits severe financial distress with stockholders' deficiency of $6.3M, extremely low cash position of $198K, and a massive debt burden of $7.1M including $2.1M in current convertible notes. Despite modest revenue growth, the company faces critical liquidity constraints and potential insolvency.
Red Flags Detected (6)
Stockholders' deficiency increased 23% to ($6.3M) indicating potential insolvency
Cash position critically low at $198K (40% decline from $334K)
$2.1M in convertible debt moved from long-term to current, creating immediate payment pressure
3 more red flags detected
Key Takeaways
Company requires immediate capital infusion to avoid potential bankruptcy
Revenue growth of 22% is positive but insufficient to offset structural financial problems
2 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.